Lisbon 2017 Delegate Registration Programme Exhibition Virtual Exhibition Satellites OneWorld Travel Discount
escrs app advert


Search Title by author or title

Features of cataract femtolaser-assisted phacoemulsification in patients with severe pseudoexfoliation syndrome

Poster Details

First Author: M.Shanturova RUSSIA

Co Author(s):    M. Tyazhev   T. Iureva                 

Abstract Details


To optimize the stage of cataract femtolaser-assisted phacoemulsification in patients with pseudoexfoliation syndrome.


S. Fyodorov Eye Microsurgery Federal State Institution, Irkutsk, Russia


The analysis of 500 femtolaser-assisted phacoemulsifications was made during 6 months in 2016. The average age of patients was 75, 6 ± 5, 7 years, among them women - 325, men - 175. 148 (29.6%) patients had a concomitant diagnosis - pseudoexfoliation syndrome, 74 (14.8%) patients - glaucoma, 6 (1.2%) - a subluxation of the lens. At the femto-stage the ophthalmic laser system of Alcon LenSx Company was used. The positioning of the main and additional corneal incisions was performed at the first step. For capsulorhexis the preset manufacturer settings of incision depth were used.


Incomplete cutting of the anterior capsule by femtolaser was one of the few problems at development stage of this technique. It was revealed that 87% of patients had pseudoexfoliation syndrome. Three-dimensional photo registration with Scheimflug - camera Oculus - Pentacam helped identify dense deposits of pseudoexfoliative material with height from 110 to 250 microns in the anterior capsule of these patients. In this connection, the parameters of the capsulorhexis at the femtostage had been changed. In manual mode, the laser was increased depth of insertion into the anterior lens capsule, namely delta down, on 150-200 microns.


Optimization of femtostage of cataract phacoemulsification in patients with pseudoexfoliative syndrome with increasing of delta down on 150-200 microns can reduce the percentage of incomplete cutting of the capsule from 10% to 1-1.5% without adversely affecting the next surgical steps.

Financial Disclosure:


Back to Poster listing